Mar 15, 2026 | Immutep LAG-3 Phase 3 Failure Crashes Stock 88%; Ultragenyx Gene Therapy Hits OTc

Immutep's LAG-3 drug eftilagimod alfa fails Phase 3 futility analysis in NSCLC—stock drops 88%. Ultragenyx DTX301 gene therapy hits co-primary endpoint in OTC deficiency. Plus: Lilly's $3B orforglipron manufacturing expansion, BridgeBio muscular dystrophy data, and four PDUFA dates ahead.Visit at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Immutep, eftilagimod alfa, LAG-3, NSCLC, Ultragenyx, DTX301, OTC deficiency, gene therapy, Eli Lilly, orforglipron, China manufacturing, BridgeBio, BBP-418, muscular dystrophy, GSK, Arexvy, RSV vaccine, Biogen, salanersen, SMA, Roche, giredestrant, Aldeyra, reproxalap, Rhythm Pharmaceuticals, IMCIVREE, Rocket Pharmaceuticals, KRESLADI, Sandoz, biosimilars, AEMS, ACC 2026, Pfizer, Lilly, Merck, BMS, Gilead